Search

Displaying results 2421 - 2430 of 10000 in total
  1. Drug

    Hexaminolevulinate

    go.drugbank.com/drugs/DB06261
    ApprovedInvestigational

    of a prior cystoscopy. … Hexaminolevulinate is an optical imaging drug. In solution form it is instilled intravesically for use with photodynamic blue light cystoscopy as an adjunct to white light cystoscopy.

  2. Drug

    Nelistotug

    go.drugbank.com/drugs/DB19334
    Investigational

    Nelistotug is under investigation in clinical trial NCT06062420 (A Platform Study of Novel Immunotherapy Combinations as First-line Treatment in Participants With PD-L1 Positive Recurrent/metastatic Squamous … Cell Carcinoma of the Head and Neck- GALAXIES H&N-202).

    Synonyms: sapiens IGHV1-69*01 (95.9%) -(IGHD)-IGHJ1*01 (90.9%) L123>T (117), CDR-IMGT [8.8.15](26-33.51-58.97-111)) (1-122) -Homo sapiens IGHG1*01 (100%), G1m17,1 CH1 K120, CH3 D12, L14 (CH1 K120 (219) (123-220), hi
  3. Drug

    Chlorpropamide

    go.drugbank.com/drugs/DB00672
    ApprovedWithdrawn

    Up to 80% of the single oral dose of chlorpropramide is metabolized, likely in the liver; 80-90% of the dose is excreted in urine as unchanged drug and metabolites. … Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor.

    Synonyms: N-(4-chlorophenylsulfonyl)-N'-propylurea, N-(p-chlorobenzenesulfonyl)-N'-propylureaCategories: Drugs Used in Diabetes
  4. Drug

    Tuparstobart

    go.drugbank.com/drugs/DB19118
    Investigational

    Tuparstobart is under investigation in clinical trial NCT05287113 (Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-line Treatment in Participants With Pd-l1-positive (CPS

    Synonyms: Anti-LAG-3 Monoclonal Antibody INCAGN02385, Immunoglobulin G1 [301-alanine,de-C-terminal-lysine], anti-(human lymphocyte activation gene-3 protein) (human-Mus musculus monoclonal INCAGN02385 γ1-chain), disulfide with human-Mus musculus monoclonal
  5. Drug

    Vanzacaftor

    go.drugbank.com/drugs/DB18373
    ApprovedInvestigational

    [L52275,A179677] Vanzacaftor was first approved by the US FDA in December 2024 in combination with another CFTR corrector - [tezacaftor], which binds to a different site than vanzacaftor - and [deutivacaftor … Vanzacaftor is a small molecule cystic fibrosis transmembrane conductance regulator (CFTR) corrector.

  6. Drug

    Gefapixant

    go.drugbank.com/drugs/DB15097
    Approved

    [L48596] Gefapixant is a novel antagonist of the P2X3 receptor that works to reduce the cough reflex in patients with chronic cough. … It received approval in both Japan and Switzerland in 2022 for the treatment of adult patients with RCC and UCC, and received subsequent approval in the EU in September 2023 for the same indications.

  7. Drug

    Tafenoquine

    go.drugbank.com/drugs/DB06608
    ApprovedInvestigational

    [A35671, A35690] It was discovered by the scientists at the Walter Reed Army Institute of Research in 1978 as a substitute for primaquine that would be more effective against relapsing vivax malaria. … Tafenoquine is an 8-aminoquinoline analogue of primaquine which varies only on the presence of a 5-phenoxy group.

  8. Drug

    Vamorolone

    go.drugbank.com/drugs/DB15114
    ApprovedInvestigational

    It is used to manage inflammation and immune dysregulation in patients with Duchenne muscular dystrophy (DMD), a neuromuscular disorder characterized by the insidious regression of neuromuscular function … Vamorolone is a novel and fully synthetic glucocorticoid developed by Santhera Pharmaceuticals.

  9. Drug

    Etuvetidigene Autotemcel

    go.drugbank.com/drugs/DB17593
    ApprovedInvestigational

    [L54693] WAS is a rare X-linked disorder caused by a mutation in the gene encoding the WAS protein, leading to a compromised immune system. … [A274878] The WAS protein is expressed on non-erythroid hematopoietic cells and regulates the function of actin filaments in the cytoskeleton.[A274878]

  10. Drug

    Pitavastatin

    go.drugbank.com/drugs/DB08860
    ApprovedInvestigational

    were found in clinical studies to result in a 45.8% to 54.6% decrease in LDL cholesterol levels. … [A181087, A181406] Pitavastatin and other drugs from the statin class of medications including [atorvastatin], [pravastatin], [rosuvastatin], [fluvastatin], and [lovastatin] are considered first-line